{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:07:46Z","timestamp":1791389266799,"version":"4.3.3"},"reference-count":9,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaip.2021.06.049","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:55:41Z","timestamp":1626414941000},"page":"4167-4169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8191","authenticated-orcid":false,"given":"Cheshil","family":"Dixit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akaluck","family":"Thatayatikom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Knutsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.06.049_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM199903043400904","article-title":"Hyper-IgE syndrome with recurrent infections\u2014an autosomal dominant multisystem disorder","volume":"340","author":"Grimbacher","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.049_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10875-017-0429-z","article-title":"Gastrointestinal manifestations of STAT3-deficient hyper-IgE syndrome","volume":"37","author":"Arora","year":"2017","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.049_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jaci.2010.06.029","article-title":"Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis","volume":"126","author":"Schimke","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.049_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaci.2008.04.037","article-title":"Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome","volume":"122","author":"Renner","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.049_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2021.06.049_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s10875-020-00751-4","article-title":"Efficacy of dupilumab for controlling severe atopic dermatitis in a patient with hyper-IgE syndrome","volume":"40","author":"L\u00e9vy","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.049_bib7","doi-asserted-by":"crossref","first-page":"108452","DOI":"10.1016\/j.clim.2020.108452","article-title":"Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome","volume":"215","author":"Sogkas","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.049_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.0105-2896.2005.00228.x","article-title":"Hyper-IgE syndromes","volume":"203","author":"Grimbacher","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2021.06.049_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821007820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821007820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:29:29Z","timestamp":1761974969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821007820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2213219821007820"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.06.049","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.06.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}